Naturally occurring NY-ESO-1-specific CD4+ and CD8+ T cell responses were typically detected only in patients who had serum antibody against NY-ESO-1, indicating that spontaneous immune responses against NY-ESO-1 in cancer patients with NY-ESO-1 expressing tumors were highly integrated [3], [4]. This evidence concerns the gene CD8A and cancer.